Marcadores bioquímicos propuestos para el estudio de la sarcopenia

Contenido principal del artículo

Silvina Mastaglia

Resumen

La sarcopenia asociada a la edad es una condición clínica  caracterizada por una disminución en la fuerza, calidad y cantidad
de masa muscular así como también en la función muscular. Un biomarcador se define como una característica que es medible objetivamente y evaluable como indicador de un proceso biológico normal, patológico o respuesta terapéutica a una intervención farmacológica. Los marcadores bioquímicos propuestos para el estudio de la sarcopenia pueden ser categorizados en dos grupos.
El primero de ellos evalúa el estatus musculoesquelético; este panel de marcadores está formado por miostatina/folistatina, procolágeno aminoterminal tipo III e índice de sarcopenia. El segundo grupo de marcadores bioquímicos evalúa factores causales, para lo cual se sugiere medir el factor de crecimiento insulino-símil tipo 1 (IGF-1), dehidroepiandrosterona (DHEAS), cortisol, factores inflamatorios [proteína C reactiva (PCR), interleuquina 6 (IL-6) y factor de necrosis tumoral (TNF-a)]. Las recomendaciones realizadas están basadas en la evidencia científica disponible en la actualidad y la disponibilidad
de la metodología apropiada para cada uno de los biomarcadores.

Detalles del artículo

Cómo citar
1.
Mastaglia S. Marcadores bioquímicos propuestos para el estudio de la sarcopenia. Actual. Osteol. [Internet]. 15 de agosto de 2023 [citado 21 de mayo de 2024];19(1):p. 9-17. Disponible en: https://ojs.osteologia.org.ar/ojs33010/index.php/osteologia/article/view/78
Sección
Actualizaciones

Citas

Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95

Ladang A, Beaudart C, Reginster JY, et al. Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcifed Tissue International 2023. https://doi.org/10.1007/s00223-022-01054-z.

Zanker J, Patel S, Blackwell T, et al. Walking speed and muscle mass estimated by the D3-creatine dilution method are important components of sarcopenia associated with incident mobility disability in older men: a classification and regression tree analysis. J Am Med Dir Assoc 2020; 21:1997-2002

Cawthon PM, Peters KE, Cummings SR, etal. Association between muscle mass determined by D3-creatine dilution and incident fractures in a prospective cohort study of older men. J Bone Miner Res 2022; 37:1213-20.

Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48:16-31.

Mancinelli R, Checcaglini F, Coscia F, et al. Biological aspects of selected myokines in skeletal muscle: focus on aging. Int J Mol Sci 2021; 22:8520.

Paris MT, Bell KE, Mourtzakis M. Myokines and adipokines in sarcopenia: understanding cross-talk between skeletal muscle and adipose tissue and the role of exercise. Curr Opin Pharmacol 2020; 52:61-6.

Fife E, Kostka J, Kroc Ł. et.al. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr 2018;18:200.

Bergen HR, Farr JN, Vanderboom PM et. al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle 2015; 5:21

He Z, Tian Y, Valenzuela PL, et al. Myokine response to high-intensity interval vs resistance exercise: an individual approach. Front Physiol 2018; 9:1735.

Kuivaniemi H, Tromp G. Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases. Gene 2019; 707:151-71.

Bhasin S, He EJ, Kawakubo M, et al. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J Clin Endocrinol Metab 2009; 94:4224-33.

Santanasto AJ, Cvejkus RK, Wojczynski MK, et al. Circulating procollagen type III N-terminal peptide and physical Function in adults from the long-life family study. J Gerontol A Biol Sci Med Sci 2021; 76:1273-79.

Berry SD, Ramachandran VS, Cawthon PM, et al. Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study. J Frailty Aging 2013; 2:129-34.

Yang J, Zhang T, Feng D, et al. A new diagnostic index for sarcopenia and its association with short-term postoperative complications in patients undergoing surgery for colorectal cancer. Color Dis 2019; 21:538-47.

Fu X, Tian Z, Wen S, et al. A new index based on serum creatinine and cystatin C is useful for assessing sarcopenia in patients with advanced cancer. Nutrition 2021; 82:111032.

Baker JF, Newman AB, Kanaya A, et al. The Adiponectin Paradox in the elderly: associations with body composition, Physical functioning, and mortality. J Gerontol Ser A Biol Sci Med Sci 2019; 74:247-53.

Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46:459-69.

Curcio F, Ferro G, Basile C, et al. Biomarkers in sarcopenia: a multifactorial approach. Exp Gerontol 2016; 85:1-8.

Kim H, Kim M, Kojima N, et al. Exercise and nutritional supplementation on community-dwelling elderly Japanese women with sarcopenic obesity: a randomized controlled trial. J Am Med Dir Assoc 2016; 17:1011-19.

Kwak JY, Hwang H, Kim SK, et al. Prediction of sarcopenia using a combination of multiple serum biomarkers. Sci Rep 2018; 8:8574.

Bagheri R, Moghadam BH, Church DD, et al. The effects of concurrent training order on body composition and serum concentrations of follistatin, myostatin and GDF11 in sarcopenic elderly men. Exp Gerontol 2020; 133:110869.

Yamada M, Nishiguchi S, Fukutani N, et al. Mail-based intervention for sarcopenia prevention increased anabolic hormone and skeletal muscle mass in community-dwelling Japanese older adults: the INE (Intervention by Nutrition and Exercise) Study. J Am Med Dir Assoc 2015; 16:654-60.

Maggio M, Lauretani F, Ceda GP. Sex hormones and sarcopenia in older persons. Curr Opin Clin Nutr Metab Care 2013; 16:3-13.

Tuttle CSL, Thang LAN, Maier AB Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev 2020; 64:101185.

Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle mass (Sarcopenia) and strength. Am J Med 2006. https://doi.org/10.1016/j.amjmed.2005.10.049

Lu Y, Niti M, Yap KB, et al. Effects of multi-domain lifestyle interventions on sarcopenia measures and blood biomarkers: secondary analysis of a randomized controlled trial of community-dwelling pre-frail and frail older adults. Aging 2021; 13:9330-47.

Sardeli AV, Tomeleri CM, Cyrino ES, et al. Effect of resistance training on inflammatory markers of older adults: a metanalysis. Exp Gerontol 2018; 111:188-96.